Cancer-focused biotech accelerator Triphase launched by FACIT and MaRS
Triphase Accelerator Corp, a cancer-focused biotechnology accelerator, has been formed by an investment partnership of Fight Against Cancer Innovation Trust (FACIT) and affiliates of commercialization and innovation hubs MaRS Innovation and MaRS Discovery District. With operations in Toronto and San Diego, Calif., Triphase aims to support differentiated products through proof of concept (Phase II) faster and more efficiently. Originally spun out of the Ontario Institute for Cancer Research in 2010, Triphase has entered into a strategic relationship with Celgene Corp, a manufacturer of drug therapies for cancer and inflammatory disorders with headquarters in Summit, New Jersey.
13 January 2014•4 mins read
